rosuvastatin vs sofosbuvir/velpatasvir
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of rosuvastatin and sofosbuvir/velpatasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin. Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.
Crestor
Epclusa
Rosuvastatin is a drug that lowers cholesterol. It helps to reduce the risk of heart problems and stroke.
Vosevi is a drug that combines three medicines into one tablet. It is used to treat hepatitis C in adults who have already tried other treatments.
Rosuvastatin is used to lower bad cholesterol (LDL) in adults and children. It can also slow down the hardening of arteries in adults. This medicine also treats high triglycerides and certain inherited cholesterol disorders.
Vosevi treats chronic hepatitis C (HCV) infection in adults. It is for those without cirrhosis or with compensated cirrhosis (Child-Pugh A). You can use it if you have genotype 1, 2, 3, 4, 5, or 6 HCV. You must have already been treated with a hepatitis C medicine containing an NS5A inhibitor, or sofosbuvir without an NS5A inhibitor (for genotypes 1a or 3).
Rosuvastatin belongs to a class of drugs called statins. It works by blocking a substance your body needs to make cholesterol. This helps to lower your cholesterol levels.
Vosevi contains sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir blocks a protein called NS5B polymerase that the hepatitis C virus needs to multiply. Velpatasvir blocks the NS5A protein, and voxilaprevir blocks the NS3/4A protease protein, both of which the virus also needs.
- • Headache
- • Nausea
- • Muscle pain
- • Weakness
- • Constipation
- • Headache
- • Fatigue (feeling tired)
- • Diarrhea
- • Nausea (feeling sick to your stomach)
- Fatigue 11,700
- Nausea 10,039
- Dyspnoea 9,208
- Diarrhoea 9,198
- Myalgia 8,784
- Feeling tired 2,307
- Hepatitis C infection 1,734
- Headache 1,639
- Feeling sick to your stomach 1,386
- Low red blood cell count 1,185
Rosuvastatin can cause muscle problems, including muscle pain, tenderness, or weakness. Tell your doctor right away if you have these symptoms, especially if you also have a fever or feel sick. Rosuvastatin can also cause liver problems. Your doctor may do blood tests to check your liver before and during treatment.
Vosevi can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Before starting Vosevi, your doctor will test you for Hepatitis B. They will also monitor you during and after treatment.
Do not take rosuvastatin if you are pregnant. It can harm your unborn baby. Talk to your doctor about other ways to control your cholesterol during pregnancy. Breastfeeding is not recommended while taking rosuvastatin.
It is not known if Vosevi can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Vosevi passes into breast milk, so discuss this with your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare rosuvastatin with
How to Read This rosuvastatin vs sofosbuvir/velpatasvir Comparison
rosuvastatin is classified in the HMG-CoA Reductase Inhibitor (Statin) drug class, while sofosbuvir/velpatasvir sits within the NS5B/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, rosuvastatin has 48,929 submissions while sofosbuvir/velpatasvir has 8,251. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to this hepatitis c medication can increase the amount of rosuvastatin that stays in your blood.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for rosuvastatin or sofosbuvir/velpatasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.